Volume 18 Issue 3, September 2024

Through its patient-data-derived Gemini digital twins, Aitia is uncovering the hidden genetic and molecular mechanisms that causally drive human disease, and accelerating the discovery of breakthrough drugs to improve outcomes for neurodegenerative disorders and cancer.

With its artificial intelligence-powered unEarth Rx platform and proprietary fungal collection, Kapoose Creek Bio is discovering the next generation of neuroactive drugs.

Brainify.AI aims to revolutionize the way mental health disorders are treated by harnessing the power of artificial intelligence/machine learning to identify electroencephalography biomarkers for precision psychiatry.

Quantum Sky is using its multifaceted platform to develop next-generation gene editors and tap into a broader biochemical space.

Causal artificial intelligence (AI) is transforming the pharma business model.

By combining ultra-throughput biochemistry and machine learning, biotech company Anagenex is discovering innovative new therapeutics.

Transcripta Bio is speeding drug discovery across all therapeutic areas by applying machine learning to its Drug–Gene Atlas.

FlowMatrix, an innovative artificial intelligence (AI)-guided high-throughput platform, is allowing rapid assessment of the effects of novel drug pairings in living cells and identifying those with the greatest potential for further testing.

Engineering antibody constant region platforms to enhance convenience and efficacy of antibody therapeutics.

Several collaborations involving large pharma companies signal renewed interest in the neuroscience sector.

Beijing Darwin Biotech’s Aleeto, an exciting new drug candidate, could become the first effective treatment for amyotrophic lateral sclerosis (ALS) and chronic stroke, devastating neurological indications for which there are currently no effective therapies.

Backed by over $230 million in funding from highly regarded biotech investors, Engrail Therapeutics aims to deliver transformational therapies that improve the lives of patients with devastating neuropsychiatric and neurodevelopmental disorders.

For almost 20 years, much biopharma dealmaking has been directed toward oncology research and development. In this feature, we review some recent trends in the area.

Asgard Therapeutics’ tumor-agnostic platform triggers cancer cells to kick-start immune responses against themselves. Achieving this in-vivo direct cell reprogramming in patients could pioneer the next generation of cell therapies.

Cancer Research Horizons (CRH) is harnessing the skills, expertise, and research network of its parent organization to speed-up the discovery and development of transformative oncology drugs, improve patient outcomes, and advance assets for biopharma partners.